Familial Defective Apolipoprotein B-100

1. Disease Information

Overview. FDB is an inherited disorder of LDL catabolism in which a mutant apoB-100 — the sole apolipoprotein of LDL and the ligand recognized by the hepatic LDL receptor — binds the receptor with reduced affinity. The consequence is delayed clearance of LDL, elevated plasma LDL-C and apoB, and an increased lifetime risk of premature coronary artery disease. Clinically it is essentially indistinguishable from heterozygous LDLR-mediated FH without molecular testing; both present with elevated LDL-C, normal triglycerides and HDL-C, tendon xanthomas, and premature atherosclerosis PMID: 18325181.

Key identifiers.

Synonyms / alternative names. Familial ligand-defective apolipoprotein B-100; familial defective apoB-100; FDB; ligand-defective apoB; hypercholesterolemia due to ligand-defective apoB. FDB is one molecular subtype within the broader clinical umbrella of autosomal dominant hypercholesterolemia (ADH) / familial hypercholesterolemia (FH), alongside LDLR and PCSK9 causes PMID: 31883481.

Data source type. The knowledge in this report derives from aggregated disease-level resources — molecular genetics studies, FH registries, population cohorts (e.g., Copenhagen General Population Study), and functional/biochemical studies — rather than individual EHR-derived patient records.

2. Etiology

Primary cause — genetic. FDB is a monogenic disorder caused by heterozygous (or, rarely, homozygous/compound heterozygous) missense variants in APOB that localize to the LDLR-binding region of apoB-100 near codon 3500. The disease is not infectious or primarily environmental; environmental/lifestyle factors modify severity but do not cause the disorder.

Genetic risk factors. - Causal variant: APOB R3500Q (c.10580G>A; rs5742904) is the classic and most frequent cause. Additional ligand-defective variants clustering in the same functional region include R3500W, R3531C, R3480W, and H3543Y PMID: 15135245; PMID: 11115503. - Zygosity: heterozygotes are affected (codominant); homozygous APOB cases exist but are rare (e.g., 4 homozygous APOB patients among 49 molecularly defined homozygous ADH cases in the Netherlands) PMID: 24585268.

Environmental / modifying risk factors. Background diet (saturated fat, cholesterol intake), obesity, smoking, and coexisting metabolic syndrome raise absolute LDL-C and cardiovascular risk on top of the genetic defect. Phenotypic expression depends jointly on the mutation and the genetic/dietary background of the population studied; ascertainment in lipid clinics overestimates the true population effect size PMID: 15528480.

Protective factors. Because the underlying lesion is impaired receptor-mediated LDL clearance, any factor that upregulates LDLR expression or lowers LDL production is protective — this is the pharmacological basis of statins, ezetimibe, and PCSK9 inhibition. Rare APOB missense variants can also lower LDL (e.g., an apoB S2429T variant proposed to have an LDL-lowering effect within an FH family), illustrating that APOB variation can push LDL in either direction PMID: 27578127; PMID: 7585299.

Gene–environment interactions. The measured LDL-C increment attributable to a given APOB or LDLR variant differs by background population and by ascertainment context — general-population carriers and clinically ascertained FH carriers differed by ~1.6 mmol/L (P=0.03) — confirming that the phenotype is a product of genotype × background/lifestyle rather than genotype alone PMID: 15528480.

3. Phenotypes

FDB phenotypes are those of heterozygous FH but generally milder.

Severity and progression. LDL-C elevation is stable/lifelong; atherosclerosis is slowly progressive. Notably, FH/high-LDL-C (including APOB R3500Q) increases myocardial-infarction risk but not ischemic stroke risk in the general population PMID: 29593013.

Quality of life. No FDB-specific EQ-5D/SF-36 data were identified. QoL impact derives chiefly from cardiovascular events and lifelong pharmacotherapy; because FDB is generally milder and later-onset than LDLR-FH, the average burden is correspondingly lower.

4. Genetic / Molecular Information

Causal gene. APOB (apolipoprotein B; HGNC:603; OMIM *107730), chromosome 2p24–23. ApoB-100 (4,536 residues in the mature protein) is the structural scaffold of VLDL/IDL/LDL and the LDLR ligand.

Pathogenic variants.

Variant classification (ACMG/AMP). R3500Q is well established as pathogenic (functional evidence of defective LDLR binding, cosegregation, founder haplotype). Several additional exon 26/29 variants (e.g., S3476L, S3488G, Y3533C, T3540M, I4350T, G4368D) have been reported as FDB-associated in Dutch cohorts and warrant case-by-case interpretation PMID: 18325181.

Allele frequency. R3500Q carrier frequency is on the order of ~0.1% (≈1 in 500–1,000) in Northern/Central European populations, lower in Southern Europe (e.g., rare in general Spain but locally enriched in Galicia due to Celtic ancestry) PMID: 12208478.

Somatic vs germline. Germline; there is no somatic component.

Functional consequence. A conformational loss-of-ligand-function: the variant does not abolish the protein but changes the local conformation around the receptor-binding site, reducing LDLR affinity to ~32% of normal PMID: 10657378. This behaves as a dominant/codominant trait because each affected allele produces defective LDL particles.

Modifier genes. Polygenic LDL-raising SNP burden and coexisting variants in other lipid genes (LDLR, PCSK9, APOE, ANGPTL3, APOC3) modulate expressivity; rare APOB variants (e.g., S2429T) may lower LDL and partially offset severity PMID: 27578127; PMID: 31883481.

Epigenetic / chromosomal. No recurrent epigenetic mechanism or chromosomal abnormality is implicated in FDB; it is a point-mutation disorder.

5. Environmental Information

• Environmental factors: No specific toxin, radiation, or occupational exposure causes FDB.
• Lifestyle factors: Dietary saturated fat/cholesterol, obesity, physical inactivity, and smoking increase absolute LDL-C and atherosclerotic risk on top of the genetic defect and are the primary modifiable levers.
• Infectious agents: None. FDB is a purely genetic, non-communicable disorder.

6. Mechanism / Pathophysiology

Ordered causal chain

1. A germline missense variant in APOB (most commonly R3500Q) is inherited → leads to an amino-acid substitution in apoB-100 at/near the LDLR-binding region.
2. The substitution disrupts the intramolecular Arg3500–Trp4369 interaction (and requires the apoB-100 C-terminus) → results in an altered local conformation of apoB-100 around the receptor-binding site (demonstrated by higher affinity for the conformation-sensitive MB47 antibody) PMID: 11115503.
3. The altered conformation → reduces binding of LDL particles to the hepatic LDL receptor (to ~32% of normal affinity) PMID: 10657378.
4. Reduced receptor binding → decreases receptor-mediated hepatic uptake/catabolism of LDL → prolongs LDL residence time in plasma.
5. Delayed clearance → raises plasma LDL-C and apoB concentrations (the biochemical phenotype).
6. Elevated (and modified/oxidized) LDL → accumulates and is retained in the arterial intima.
7. Retained LDL → is internalized by macrophages → drives foam-cell formation and an immune-inflammatory response PMID: 33959626.
8. Chronic foam-cell/inflammatory burden → produces atherosclerotic plaques → manifests clinically as tendon xanthomas and premature coronary artery disease PMID: 18325181.

APOB R3500Q mutation
   │ (disrupts Arg3500–Trp4369)
   ▼
apoB-100 conformational change near LDLR-binding site   [upstream, causal]
   ▼
↓ LDL–LDLR binding affinity (~32% of normal)
   ▼
↓ hepatic LDL clearance → ↑ LDL residence time
   ▼
↑ plasma LDL-C / apoB
   ▼
arterial intimal LDL retention ──► macrophage uptake ──► foam cells + inflammation
   ▼
atherosclerosis ──► tendon xanthomas + premature CAD   [downstream, clinical]

Upstream vs downstream. The conformational defect and reduced receptor binding are the upstream initiating lesions; hypercholesterolemia is the intermediate biochemical readout; foam-cell formation and atherosclerosis are downstream consequences shared with all LDL-driven hypercholesterolemias.

Molecular pathways / cellular processes. Receptor-mediated endocytosis of LDL (KEGG hsa04979, "Cholesterol metabolism"); reverse cholesterol transport (ABCA1-mediated efflux); macrophage lipid handling and NF-κB-driven vascular inflammation are engaged downstream PMID: 33568202; PMID: 36838686.

Protein dysfunction. Conformational loss-of-ligand-function of apoB-100 (not misfolding/aggregation, not loss of expression). UniProt P04114 (APOB_HUMAN).

Metabolic changes. Isolated elevation of LDL-C and apoB with characteristically normal triglycerides and HDL-C — distinguishing FDB from combined hyperlipidemias.

Suggested ontology terms. GO:0006629 (lipid metabolic process); GO:0034383 (low-density lipoprotein particle clearance); GO:0006898 (receptor-mediated endocytosis); GO:0034364 (low-density lipoprotein particle); CHEBI:39025 (low-density lipoprotein). Cell types: CL:0000182 (hepatocyte), CL:0000235 (macrophage/foam cell), CL:0000891 (aortic/vascular smooth muscle context).

7. Anatomical Structures Affected

• Primary organ: Liver (hepatocytes) — the principal site of LDL-receptor-mediated clearance whose function is bypassed by the defective ligand. UBERON:0002107 (liver); CL:0000182 (hepatocyte).
• Secondary/target organs: Arterial wall, especially coronary arteries (and femoral/peripheral arteries). UBERON:0001981 (blood vessel); UBERON:0001621 (coronary artery). Femoral intima-media thickness is increased in FH patients including APOB defects, in relation to mutational class PMID: 18096825.
• Body systems: Cardiovascular (atherosclerosis, CAD) and integumentary/musculoskeletal (tendon xanthomas). Blood/plasma lipoprotein compartment is the biochemical stage.
• Tissue/cell level: Vascular intima (connective tissue), arterial macrophages/foam cells (CL:0000235), and hepatocytes.
• Subcellular: Plasma-membrane LDL receptor and clathrin-coated pits (GO:0005905); endosomes/lysosomes for LDL degradation (GO:0005764). The extracellular lipoprotein particle (GO:0034364) is the affected entity.
• Lateralization: Systemic/bilateral (xanthomas often symmetric); vascular disease is diffuse rather than lateralized.

8. Temporal Development

• Onset: The biochemical trait (elevated LDL-C/apoB) is congenital and lifelong. Clinical complications are adult-onset, typically later than in LDLR-FH.
• Onset pattern: Chronic/insidious.
• Progression: Slowly progressive atherosclerosis. FDB CHD occurs at a mean age of ~52 years versus ~41 years in LDLR-FH, and far less frequently (5.6% vs 41.8%) PMID: 25126774.
• Course: Stable biochemical elevation with progressive vascular risk; chronic lifelong disease.
• Critical window: Cumulative LDL exposure drives risk, so the critical period for intervention is early and sustained LDL lowering from young adulthood (or childhood in higher-risk cases), before substantial plaque burden accrues.

9. Inheritance and Population

Inheritance. Autosomal dominant / codominant; heterozygotes are affected. Homozygous/compound-heterozygous APOB cases are rare and more severe PMID: 24585268.

Penetrance / expressivity. Biochemical penetrance is high but expressivity is variable — some carriers have LDL-C within the normal range, and clinical FH scores (Dutch Lipid Clinic Network, Simon Broome) have low sensitivity for APOB variants (DLCN sensitivity 13.8%; SBDC 22.5%) PMID: 30270060; PMID: 18279815.

Founder effect. R3500Q is a single European founder mutation ~6,000–7,000 years old (≈270 generations); all probands are identical-by-descent, carried on the rare APOB haplotype 194 (XbaI−/MspI+/EcoRI−) PMID: 9339363; PMID: 12208478.

Epidemiology. Estimated carrier frequency ~0.1% (≈1 in 500–1,000) in Northern/Central Europe; combined LDLR+APOB FH prevalence ~1 in 125–135 in Switzerland, with FDB a minority subtype PMID: 30270060. FDB is a minor cause of clinically diagnosed FH in Southern Europe (e.g., 1.4% of Spanish clinical-FH probands; population prevalence ~2.8×10⁻⁵), but locally enriched in Galicia PMID: 12208478; PMID: 16596945.

Population distribution of variants. R3500Q predominates in European-descent populations; R3500W is the major ligand-defective APOB variant in East Asians (identified in 8 Taiwanese FH probands; heterozygote prevalence 2.4% vs 0.3% for R3500Q in Chinese hyperlipidemics) PMID: 20538126; PMID: 10998466.

Sex ratio / consanguinity. No strong sex bias (autosomal dominant); consanguinity is not required for the dominant heterozygous phenotype but underlies rare homozygous cases.

10. Diagnostics

Laboratory. Elevated LDL-C and apoB with normal triglycerides and HDL-C (LOINC: 13457-7 LDL-C; 1884-6 apoB) PMID: 18325181. A functional flow-cytometric LDL-ligand assay can detect heterozygous FDB by demonstrating reduced LDL binding PMID: 10657378.

Genetic testing (definitive). FDB cannot be distinguished clinically from LDLR-FH and requires molecular confirmation PMID: 18325181. Approaches: - Targeted single-variant/codon-3500 assays (PCR-RFLP, high-resolution melting) for R3500Q/H3543Y PMID: 18325181. - NGS FH gene panels covering LDLR, APOB, PCSK9 (± LDLRAP1, ABCG5/8) PMID: 41412630; PMID: 41760042. - WES/WGS are useful when panels are negative.

Clinical criteria & differential diagnosis. DLCN and Simon Broome criteria are standard for FH but under-detect FDB PMID: 30270060. Differential diagnosis includes LDLR-mediated FH, PCSK9 gain-of-function FH, polygenic hypercholesterolemia, familial combined hyperlipidemia PMID: 34906840, and rare recessive/other catabolic defects (a clinical HoFH phenotype has been reported with intact apoB/LDLR, implying additional catabolic genes) PMID: 9626156.

Screening. Cascade (reverse-cascade) screening of first-degree relatives after an index molecular diagnosis is the key strategy; universal newborn/pediatric screening for FH is supported by healthcare professionals but not yet routine PMID: 41251905; PMID: 41608359.

11. Outcome / Prognosis

• Survival/mortality: No FDB-specific survival tables identified. Prognosis is driven by cardiovascular event risk, which is lower and later than in LDLR-FH.
• Morbidity: Premature CAD is the dominant morbidity; CHD prevalence ~5.6% in FDB vs 41.8% in LDLR-FH PMID: 25126774. FH/high LDL-C raises myocardial infarction risk but not ischemic stroke risk PMID: 29593013.
• Prognostic factors: Mutational class (null LDLR alleles > receptor-defective > APOB defects for atherosclerosis severity and LDL-C), absolute/cumulative LDL-C, age, sex, smoking, and blood pressure PMID: 18096825; PMID: 28475941.
• Recovery potential: With early sustained LDL lowering, cardiovascular risk is substantially reducible; the intact LDL receptor predicts good pharmacologic response.

12. Treatment

FDB is managed as heterozygous FH, and — critically — because the LDL receptor itself is intact, LDLR-upregulating therapies are highly effective.

Rationale. "There is today a large availability of drugs (i.e., statins, ezetimibe and PCSK9 inhibitors) allowing theoretically the normalization of plasma LDL cholesterol levels in this population" PMID: 30910740. Because FDB LDL clearance depends on functional LDLR, upregulating the receptor compensates for the ligand defect — mechanistically supported by the observation that "Mevastatin increased, whereas rPCSK9 reduced LDLR expression. The PCSK9-neutralizing antibody restored LDLR expression" PMID: 29284604.

Experimental / advanced. Gene- and cell-based therapies (LDLR gene delivery, CRISPR/Cas9 editing) are in development primarily for homozygous FH; RNA therapies and MTP/ANGPTL3-directed agents extend options for severe/refractory disease PMID: 36572377; PMID: 30910740.

Personalized medicine. Molecular subtyping (APOB vs LDLR-null vs LDLR-defective) informs prognosis and intensity of therapy; genotype-guided cascade screening extends benefit to relatives PMID: 41412630.

13. Prevention

• Primary prevention: Lifelong healthy diet, avoidance of smoking, weight and blood-pressure control to minimize cumulative atherosclerotic risk.
• Secondary prevention (early detection): Reverse-cascade genetic and lipid screening of relatives after an index diagnosis; consideration of pediatric/newborn FH screening PMID: 41251905; PMID: 41608359.
• Tertiary prevention: Aggressive LDL lowering (statin ± ezetimibe ± PCSK9 inhibitor) to prevent CAD progression and events.
• Genetic counseling: 50% transmission risk per offspring (autosomal dominant); counseling supports family planning and cascade testing PMID: 41412630.

14. Other Species / Natural Disease

• Taxonomy/orthologs: APOB is conserved across mammals (human APOB, NCBI Gene 338; mouse Apob, NCBI Gene 238). No specific naturally occurring animal disease attributable to an APOB R3500Q-equivalent variant was identified in this investigation.
• Comparative biology: The apoB-100/LDLR clearance axis is evolutionarily conserved, and the mechanism has been functionally validated in transgenic mice expressing human R3500Q and W4369Y apoB, which reproduce the defective LDLR binding PMID: 11115503.
• Transmission/zoonosis: Not applicable — non-communicable genetic disorder.

15. Model Organisms

• Transgenic mice: Mice expressing human apoB-100 carrying R3500Q (and the complementary W4369Y) were pivotal in defining the mechanism — LDL from both showed identically defective LDLR binding and increased MB47 antibody affinity, demonstrating the Arg3500–Trp4369 conformational interaction PMID: 11115503.
• In vitro / cellular models: Cultured cells (e.g., fibroblasts, HepG2-type systems) are used to quantify LDLR expression and LDL binding under statin/PCSK9 modulation, and to test LDLR-upregulating therapeutics PMID: 29284604. Macrophage foam-cell models (e.g., RAW264.7, ApoE-deficient mouse aortas) recapitulate the downstream atherosclerotic steps PMID: 33568202; PMID: 36838686.
• Phenotype recapitulation: Transgenic mice faithfully reproduce the ligand-binding defect (the core lesion). Limitation: murine lipoprotein metabolism differs from human, so absolute LDL-C phenotype and atherosclerosis burden require sensitized backgrounds (e.g., ApoE-deficient) and do not fully mirror human clinical disease.
• Resources: MGI (mouse Apob), Cellosaurus/ATCC (cell lines).

Mechanistic Model / Interpretation

FDB is best understood as a ligand-side mirror image of LDLR-mediated FH: in classic FH the receptor is broken, whereas in FDB the ligand (apoB-100) is broken. Both converge on the same downstream pathology — impaired LDL clearance → hypercholesterolemia → arterial LDL retention → foam cells → atherosclerosis — but they differ quantitatively. The single conformational contact point (Arg3500–Trp4369) is the linchpin: substituting Arg3500 (a specific arginine, not merely any positive charge) collapses the receptor-competent conformation, cutting binding to ~32% of normal. Because only the ligand on the mutant allele is defective and the receptor pool is fully functional, (a) heterozygotes retain substantial clearance capacity (hence a milder phenotype and frequent underdiagnosis), and (b) upregulating the intact receptor pharmacologically (statins, PCSK9 inhibitors) efficiently rescues clearance. This mechanistic logic explains, in one coherent chain, the biochemistry, the milder-than-LDLR-FH clinical course, and the excellent drug response.

Evidence Base

Limitations and Knowledge Gaps

1. No primary omics data were analyzed in this investigation; conclusions rest on literature synthesis of genetics, biochemistry, and clinical registries.
2. FDB-specific epidemiology is imprecise — carrier-frequency estimates vary widely by population and ascertainment; robust general-population prevalence figures for R3500Q specifically remain limited.
3. Nomenclature ambiguity — legacy (R3500Q) vs mature-protein (R3527Q) vs full-length numbering can cause confusion; reports should standardize to HGVS.
4. Variant classification for non-R3500Q APOB variants (e.g., the Dutch exon-26/29 variants) is incomplete; several remain of uncertain functional impact.
5. No dedicated QoL, survival, or mortality datasets specific to FDB were located.
6. Model-organism fidelity — transgenic mice capture the ligand defect but not the full human atherosclerotic phenotype without sensitizing backgrounds.
7. Non-European populations are under-studied; R3500W in East Asians is documented but broad allelic surveys are sparse.

Proposed Follow-up Experiments / Actions

1. Query gnomAD directly for population-stratified allele frequencies of rs5742904 (R3500Q) and R3500W to quantify carrier frequencies with confidence intervals.
2. Pull ClinVar/ClinGen classifications for all APOB codon-3480 to 3543 variants to build a definitive pathogenicity table with ACMG criteria.
3. Systematic outcomes meta-analysis comparing cardiovascular event rates and treated LDL-C in molecularly confirmed FDB vs LDLR-FH cohorts (e.g., SAFEHEART, DIAMOND-FH data).
4. Structural analysis (AlphaFold/PDB) of the apoB-100 receptor-binding region to visualize the Arg3500–Trp4369 contact and model each ligand-defective variant's disruption.
5. Real-world PCSK9-inhibitor response study in genotyped FDB patients to confirm the predicted superior response given intact LDLR.
6. Cascade-screening yield analysis to quantify how many relatives per index FDB case are newly diagnosed and treated, informing cost-effectiveness of molecular-first screening.

Report compiled from 40 reviewed papers and 6 confirmed findings across 5 investigation iterations. Evidence types span human clinical/registry studies, transgenic mouse and in-vitro functional work, and population genetics. All mechanistic and clinical claims are cited to primary literature (PMIDs above).

Artifacts

• OpenScientist final report
• OpenScientist final report

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

• MONDO:0007751 (3 mentions) - the report calls it "if available", "MONDO"; MONDO calls it hypercholesterolemia, autosomal dominant, type B
• CL:0000891 (1 mention) - the report calls it "aortic/vascular smooth muscle context"; CL calls it foam cell
• GO:0005905 (1 mention) - the report calls it "Subcellular: Plasma-membrane LDL receptor and clathrin-coated pits"; GO calls it clathrin-coated pit**

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• HP:0001229 (1 mention) - HP does not contain this term

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

• GO:0034364 (2 mentions) - the report calls it "low-density lipoprotein particle"; GO calls it high-density lipoprotein particle
• CHEBI:39025 (1 mention) - the report calls it "low-density lipoprotein"; CHEBI calls it high-density lipoprotein
• CL:0000235 (2 mentions) - the report calls it "macrophage/foam cell"; CL calls it macrophage

Terms named inconsistently

The report gives these identifiers more than one name of its own:

• MONDO:0007751 - called "if available", "MONDO"